Chair: Prof Stephen Clarke
Dr Adnan Nagrial, Crown Princess Mary Cancer Centre Westmead - "Managing patients with non-mutation 2nd line NSCLC"
Dr Steven Kao, Chris O'Brien Lifehouse - "2nd line ALK and NSCLC - approach to targeted therapies"
Speakers: Tim Hucker & Paul Glare
This symposium will be an update on the current management of cancer pain, exploring the current basis of treatment and its limitations and discussing alternative management options in common practice in the U.S.A and Europe. The first session by Professor Paul Glare will discuss Opiate medication, its development as the mainstay of cancer pain management and the W.H.O model. Despite this development, opioids have limited efficacy and the model of cancer pain management has not changed despite the enormous progress seen in oncology treatment. Furthermore, with oncological advances the profile of the patient during or post cancer treatment specifically has changed drastically in the lifespan of the W.H.O model. Additionally, the landscape of opiate misuse has changed drastically with Australia experiencing an “opioid epidemic”. Chronic non-cancer pain management has altered in this time to carefully protocolised opioid therapy. Cancer pain management is still considered as a separate entity to non-cancer pain management, however, considerable overlap exists with the oncology patient experiencing multiple non oncological morbidities. Many further similarities exist between these populations and therefore chronic non-cancer pain management can be adapted to provide multidisciplinary, efficacious and non opioid based pain solutions in patients with cancer. The second session from Dr Tim Hucker will discuss non opioid medication and interventional options for cancer pain management. europathic pain is prevalent in cancer, either from the cancer itself or its treatment and throughout the cancer journey. Even in survivorship, neuropathic pain is common and persistent. The limitation of efficacy in opiate management of neuropathic pain will be highlighted. Despite being part of cancer pain management guidelines and contrary to other countries, interventional pain options are infrequently considered. There are a wide variety of pain syndromes in the cancer patient and interventional options exist in many situations. The careful application of interventional techniques in this population will aid efficacy and also assist in limiting opiate related side effects and wider opiate burden.
This breakfast session is supported by Medtronic
10:20 AM Panel Discussion
This sessions follows a highly successful format used at previous meetings. It is designed to provide a forum for discussion of the complex issues which arise in the care of patients undergoing immunotherapy treatment. The facilitators will present a series of challenging clinical cases and engage members of the multidisciplinary panel in discussion. There will also be opportunities for members of the audience to contribute to the discussion. Panellists will include a medical oncologist, radiation oncologist, surgeon, palliative care physician, nurse, psycho-oncologist and consumer.
Tom Reeve Oration